The Evoclin Foam, 1 per cent, market achieved annual sales of approximately $12.0 million
Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (US FDA) for Clindamycin Phosphate Foam, 1 per cent, the generic version of Evoclin 1 Foam, 1 per cent, of Mylan Pharmaceuticals. The medication is used to treat acne.
According to IQVIATM sales data for the 12 months ending July 2021, the Evoclin Foam, 1 per cent, market achieved annual sales of approximately $12.0 million.
Glenmark’s current portfolio consists of 173 products authorised for distribution in the US marketplace and 47 ANDA’s pending approval with the US FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.
